m6A-centered Drug Response Information

General Information of the Drug (ID: M6ADRUG0072)
Name
ML-210
Synonyms
ML-210; ML 210; [4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone; ML210; (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(5-methyl-4-nitroisoxazol-3-yl)methanone; CHEMBL1951048; CID 49766530; BRD7528; BRD-7528; TL_HRAS26; MLS003265661; SCHEMBL21965947; CHEBI:92034; HMS3874L03; BCP29439; EX-A3516; BDBM50547193; MFCD22666407; ZINC73278737; NCGC00386679-01; NCGC00386679-02; BM170835; BS-51618; SMR001941104; HY-100003; ML 210, >=98% (HPLC); CS-0017911; S0788; D83838; BRD-K01877528-001-01-6; BRD-K01877528-001-02-4; BRD-K01877528-001-03-2; BRD-K01877528-001-04-0; BRD-K01877528-001-07-3; BRD-K01877528-001-08-1; BRD-K01877528-001-09-9; BRD-K01877528-001-11-5; Q27163827; [4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone; [4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-(5-methyl-4-nitro-3-isoxazolyl)methanone; CID 49766530; CID-49766530; CID49766530; ML-210; ML 210
    Click to Show/Hide
Status Investigative [1]
Structure
Formula
C22H20Cl2N4O4
InChI
InChI=1S/C22H20Cl2N4O4/c1-14-20(28(30)31)19(25-32-14)22(29)27-12-10-26(11-13-27)21(15-2-6-17(23)7-3-15)16-4-8-18(24)9-5-16/h2-9,21H,10-13H2,1H3
InChIKey
VIBHJPDPEVVDTB-UHFFFAOYSA-N
PubChem CID
49766530
Full List of m6A Targets Related to This Drug
CDR1 antisense RNA (CDR1-AS)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene [2]
Response Summary CDR1 antisense RNA (CDR1-AS) a regulator of miR-7, as a hallmark of melanoma progression. CDR1as depletion results from epigenetic silencing of LINC00632, its originating long non-coding RNA (lncRNA) and promotes invasion in vitro and metastasis in vivo through a miR-7-independent, IGF2BP3-mediated mechanism. IGF2BP3 interacts with CDR1as and mediates invasion induced by CDR1as depletion. CDR1asHigh melanoma cell lines were strikingly more sensitive to three different GPX4 inhibitors, which are known to elicit ferroptotic cell death.
Responsed Disease Melanoma ICD-11: 2C30
 Disease Info 
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
In-vitro Model 451Lu Cutaneous melanoma Homo sapiens CVCL_6357
501-mel Melanoma Homo sapiens CVCL_4633
A-375 Amelanotic melanoma Homo sapiens CVCL_0132
SK-MEL-147 Melanoma Homo sapiens CVCL_3876
SK-MEL-173 Melanoma Homo sapiens CVCL_6090
SK-MEL-2 Melanoma Homo sapiens CVCL_0069
SK-MEL-239 Melanoma Homo sapiens CVCL_6122
SK-MEL-28 Cutaneous melanoma Homo sapiens CVCL_0526
WM115 Melanoma Homo sapiens CVCL_0040
WM1361A Cutaneous melanoma Homo sapiens CVCL_6788
WM1552C Cutaneous melanoma Homo sapiens CVCL_6472
WM266-4 Melanoma Homo sapiens CVCL_2765
WM278 Cutaneous melanoma Homo sapiens CVCL_6473
WM35 Melanoma Homo sapiens CVCL_0580
WM793b (Immunodeficient mice Cell Type melanocyte)
WM902B Melanoma Homo sapiens CVCL_6807
In-vivo Model 4-6 weeks old NOD/Shi-scid/IL-2Rgamma null (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG)) mice (female).
References
Ref 1 Machine learning approach informs biology of cancer drug response. BMC Bioinformatics. 2022 May 17;23(1):184. doi: 10.1186/s12859-022-04720-z.
Ref 2 Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell. 2020 Jan 13;37(1):55-70.e15. doi: 10.1016/j.ccell.2019.12.007.